|
|
 |
|
 |
|
| 1 |
Kamada S, Sakamoto S, Ando K, Muroi A, Fuse M, Kawamura K, Imamoto T, Suzuki H, Nagata M, Nihei N, Akakura K, Ichikawa T. Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade. J Urol. 2015 Nov;194(5):1264-70. doi: 10.1016/j.juro.2015.03.120. Epub 2015 Apr 7. PubMed PMID: 25861958. |
| 2 |
Namekawa T, Fukasawa S, Komaru A, Kobayashi M, Imamura Y, Ohzeki T, Takagi K, Sato Y, Akakura K, Ichikawa T, Ueda T. Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events. Int J Clin Oncol. 2015 Dec;20(6):1185-91. doi: 10.1007/s10147-015-0831-6. Epub 2015 Apr 28. PubMed PMID: 25917775. |
| 3 |
Nishikawa R, Goto Y, Kurozumi A, Matsushita R, Enokida H, Kojima S, Naya Y, Nakagawa M, Ichikawa T, Seki N. MicroRNA-205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer. Int J Urol. 2015 Sep;22(9):867-77. doi: 10.1111/iju.12829. Epub 2015 Jun 7. PubMed PMID: 26059417.. |
| 4 |
Kato M, Goto Y, Matsushita R, Kurozumi A, Fukumoto I, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, Ichikawa T, Seki N. MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. Int J Oncol. 2015 Aug;47(2):710-8. doi: 10.3892/ijo.2015.3043. Epub 2015 Jun 10. PubMed PMID: 26063484. |
| 5 |
Suzuki S, Tatsuno I, Oohara E, Nakayama A, Komai E, Shiga A, Kono T, Takiguchi T, Higuchi S, Sakuma I, Nagano H, Hashimoto N, Mayama T, Koide H, Sasano H, Nakatani Y, Imamoto T, Ichikawa T, Yokote K, Tanaka T. GERMLINE DELETION OF ARMC5 IN FAMILIAL PRIMARY MACRONODULAR ADRENAL HYPERPLASIA. Endocr Pract. 2015 Oct;21(10):1152-60. doi: 10.4158/EP15756.OR. Epub 2015 Jul 27. PubMed PMID: 26214113. |
| 6 |
Kaga M, Utsumi T, Tanaka T, Kono T, Nagano H, Kawamura K, Kamiya N, Imamoto T, Nihei N, Naya Y, Suzuki H, Ichikawa T. Risk of New-Onset Dyslipidemia After Laparoscopic Adrenalectomy in Patients with Primary Aldosteronism. World J Surg. 2015 Dec;39(12):2935-40. doi: 10.1007/s00268-015-3197-z. PubMed PMID: 26296835. |
| 7 |
Goto Y, Kojima S, Nishikawa R, Kurozumi A, Kato M, Enokida H, Matsushita R, Yamazaki K, Ishida Y, Nakagawa M, Naya Y, Ichikawa T, Seki N. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. Br J Cancer. 2015 Sep 29;113(7):1055-65. doi: 10.1038/bjc.2015.300. Epub 2015 Sep 1. PubMed PMID: 26325107. |
| 8 |
Yamada Y, Sakamoto S, Sazuka T, Goto Y, Kawamura K, Imamoto T, Nihei N, Suzuki H, Akakura K, Ichikawa T. Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men. Int J Urol. 2016 Jan;23(1):49-54. doi: 10.1111/iju.12952. Epub 2015 Oct 8. PubMed PMID: 26450768. |
| 9 |
Namekawa T, Utsumi T, Kawamura K, Kamiya N, Imamoto T, Takiguchi T, Hashimoto N, Tanaka T, Naya Y, Suzuki H, Ichikawa T. Clinical predictors of prolonged postresection hypotension after laparoscopic adrenalectomy for pheochromocytoma. Surgery. 2016 Mar;159(3):763-70. doi: 10.1016/j.surg.2015.09.016. Epub 2015 Oct 21. PubMed PMID: 26477475. |
| 10 |
Kurozumi A, Goto Y, Matsushita R, Fukumoto I, Kato M, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, Ichikawa T, Seki N. Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. Cancer Sci. 2016 Jan;107(1):84-94. doi: 10.1111/cas.12842. Epub 2015 Dec 5. PubMed PMID: 26509963; PubMed Central PMCID: PMC4724812. |
| 11 |
Miyoshi Y, Uemura H, Umemoto S, Sakamaki K, Taguri M, Suzuki K, Shibata Y, Masumori N, Ichikawa T, Mizokami A, Sugimura Y, Nonomura N, Sakai H, Honma S, Harada M, Kubota Y. Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naive prostate cancer. Prostate. 2016 Mar;76(4):376-82. doi: 10.1002/pros.23129. Epub 2015 Nov 30. PubMed PMID: 26616365. |
| 12 |
Xu M, Sakamoto S, Matsushima J, Kimura T, Ueda T, Mizokami A, Kanai Y, Ichikawa T. Upregulation of LAT1 during anti-androgen therapy contribute to progression in prostate cancer cells. J Urol. 2015 Dec 9. pii: S0022-5347(15)05395-1. doi: 10.1016/j.juro.2015.11.071. [Epub ahead of print] PubMed PMID: 26682754. |
| 13 |
Namekawa T, Imamoto T, Kato M, Sazuka T, Fuse M, Sakamoto S, Kawamura K, Ichikawa T. Testicular function among testicular cancer survivors treated with cisplatin-based chemotherapy. Reprod Med Biol 2015. DOI：10.1007／s12522-015-0232-6. |
| 14 |
Kurozumi A, Kato M, Goto Y, Matsushita R, Nishikawa R, Okato A, Fukumoto I, Ichikawa T, Seki N. Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J Oncol. 2016 Mar 15. doi: 10.3892/ijo.2016.3440. [Epub ahead of print] PubMed PMID: 26983694. |
| 15 |
Mizuno K, Seki N, Mataki H, Matsushita R, Kamikawaji K, Kumamoto T, Takagi K, Goto Y, Nishikawa R, Kato M, Enokida H, Nakagawa M, Inoue H. Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma. Int J Oncol. 2016 Feb;48(2):450-60. doi: 10.3892/ijo.2015.3289. Epub 2015 Dec 14. PubMed PMID: 26676674; PubMed Central PMCID: PMC4725458. |
| 16 |
Zhang Y, Toneri M, Ma H, Yang Z, Bouvet M, Goto Y, Seki N, Hoffman RM. Real-Time GFP Intravital Imaging of the Difference in Cellular and Angiogenic Behavior of Subcutaneous and Orthotopic Nude-Mouse Models of Human PC-3 Prostate Cancer. J Cell Biochem. 2016 Mar 25. doi: 10.1002/jcb.25547. [Epub ahead of print] PubMed PMID: 27012365. |
| 17 |
Fukumoto I, Kikkawa N, Matsushita R, Kato M, Kurozumi A, Nishikawa R, Goto Y, Koshizuka K, Hanazawa T, Enokida H, Nakagawa M, Okamoto Y, Seki N. Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. J Hum Genet. 2016 Feb;61(2):109-18. doi: 10.1038/jhg.2015.120. Epub 2015 Oct 22. PubMed PMID: 26490187. |
| 18 |
Nishikawa R, Chiyomaru T, Enokida H, Inoguchi S, Ishihara T, Matsushita R, Goto Y, Fukumoto I, Nakagawa M, Seki N. Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. FEBS Lett. 2015 Jul 22;589(16):2136-45. doi: 10.1016/j.febslet.2015.06.005. Epub 2015 Jun 19. PubMed PMID: 26096783. |
| 19 |
Matsushita R, Seki N, Chiyomaru T, Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataki H, Tatarano S, Itesako T, Nakagawa M, Enokida H. Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer. Br J Cancer. 2015 Jul 14;113(2):282-9. doi: 10.1038/bjc.2015.195. Epub 2015 Jun 9. PubMed PMID: 26057453; PubMed Central PMCID: PMC4506384. |
| 20 |
Yamamoto N, Nishikawa R, Chiyomaru T, Goto Y, Fukumoto I, Usui H, Mitsuhashi A, Enokida H, Nakagawa M, Shozu M, Seki N. The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. Int J Oncol. 2015 Jul;47(1):325-34. doi: 10.3892/ijo.2015.2986. Epub 2015 May 5. PubMed PMID: 25955017. |
|
|
|
|
|
|
|
|
|
|
|
|
